Â¥
6.50
Sep 30
Business Description
Tus-Pharmaceutical Group Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE000000701
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.09 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | 24.23 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 2.6 | |||||
Beneish M-Score | -2.6 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.7 | |||||
3-Year EBITDA Growth Rate | 14.1 | |||||
3-Year Book Growth Rate | 3.9 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 94.41 | |||||
9-Day RSI | 84.87 | |||||
14-Day RSI | 76.79 | |||||
6-1 Month Momentum % | -29.76 | |||||
12-1 Month Momentum % | -40.72 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.09 | |||||
Quick Ratio | 1.49 | |||||
Cash Ratio | 0.81 | |||||
Days Inventory | 271.86 | |||||
Days Sales Outstanding | 16.65 | |||||
Days Payable | 152.59 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -0.08 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 49.74 | |||||
Operating Margin % | -2.05 | |||||
Net Margin % | -1.25 | |||||
FCF Margin % | 0.46 | |||||
ROE % | -0.64 | |||||
ROA % | -0.4 | |||||
ROIC % | 301.74 | |||||
3-Year ROIIC % | -0.35 | |||||
ROC (Joel Greenblatt) % | 1.35 | |||||
ROCE % | 0.44 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shiller PE Ratio | 162.5 | |||||
PS Ratio | 4.3 | |||||
PB Ratio | 2.23 | |||||
Price-to-Tangible-Book | 3.55 | |||||
Price-to-Free-Cash-Flow | 928.58 | |||||
Price-to-Operating-Cash-Flow | 69.14 | |||||
EV-to-EBIT | 338.41 | |||||
EV-to-EBITDA | 338.41 | |||||
EV-to-Revenue | 3.71 | |||||
EV-to-FCF | 811.24 | |||||
Price-to-Projected-FCF | 2.62 | |||||
Price-to-Median-PS-Value | 0.51 | |||||
Price-to-Net-Current-Asset-Value | 17.57 | |||||
Earnings Yield (Greenblatt) % | 0.3 | |||||
FCF Yield % | 0.11 | |||||
Forward Rate of Return (Yacktman) % | 16.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Tus-Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ¥) | 361.251 | ||
EPS (TTM) (Â¥) | -0.019 | ||
Beta | 0.63 | ||
Volatility % | 41.96 | ||
14-Day RSI | 76.79 | ||
14-Day ATR (Â¥) | 0.260135 | ||
20-Day SMA (Â¥) | 5.4405 | ||
12-1 Month Momentum % | -40.72 | ||
52-Week Range (Â¥) | 4.8 - 11.25 | ||
Shares Outstanding (Mil) | 239.47 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Tus-Pharmaceutical Group Co Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Tus-Pharmaceutical Group Co Ltd Stock Events
Event | Date | Price(Â¥) | ||
---|---|---|---|---|
No Event Data |
Tus-Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Tus-Pharmaceutical Group Co Ltd(SZSE:000590)'s stock price today?
When is next earnings date of Tus-Pharmaceutical Group Co Ltd(SZSE:000590)?
Does Tus-Pharmaceutical Group Co Ltd(SZSE:000590) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |